Antibiotics Archives - Newcells Biotech

Newcells Biotech

Newcells Biotech Win Phase II of CRACK IT Challenge 29: ImmuLiver

Newcells hiPSC lung models; Valuable tools in understanding health impacts of air pollution

Newcells Biotech acquires IP for Retinal Organoids from Newcastle University

Vision for the Future of Childhood Retinal Dystrophies

Newcells Biotech Ltd. RPE Model to Improve Drug Retinal Toxicity Assessment

Dr Frank Armstrong appointed as Non-executive Director

iPSC derived retinal organoids: A Promising Tool for Modelling Retinitis Pigmentosa

Newcells Biotech technology: the fight against antibacterial resistance

Newcells Biotech Win Phase I of CRACK IT Challenge 29: ImmuLiver – Securing £99,711 Funding

Looking Forward: A Year in Review

Antibacterial resistance

BY Newcells Biotech

Newcells Biotech technology: the fight against antibacterial resistance

Antibacterial resistance is an ever-increasing concern for today’s society. As more bacterial strains become resistant to greater numbers of antibiotics, we could see modern-day healthcare rewind back to the mid-1940’s, when antibiotics